Skip to main content
Contact Us
Subscribe
E-Edition
35°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
49.02
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Nov 27, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
7,479
Open
49.02
Bid (Size)
49.07 (21)
Ask (Size)
49.15 (1)
Prev. Close
49.02
Today's Range
49.02 - 49.02
52wk Range
48.42 - 81.44
Shares Outstanding
2,222,113,553
Dividend Yield
4.65%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Bristol-Myers Squibb Unusual Options Activity
November 27, 2023
Via
Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
November 27, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
Performance
YTD
-32.16%
-32.16%
1 Month
-4.35%
-4.35%
3 Month
-20.47%
-20.47%
6 Month
-23.06%
-23.06%
1 Year
-38.06%
-38.06%
More News
Read More
3 Resilient Stocks with Massive Potential to Boost Your Wealth
November 26, 2023
Via
InvestorPlace
Don't Wait for a Market Crash: These 2 Top Stocks Are on Sale
November 24, 2023
Via
The Motley Fool
$1M Bet On Iridium Communications? Check Out These 3 Stocks Insiders Are Buying
November 22, 2023
Via
Benzinga
Exploring NYSE:BMY's dividend characteristics.
November 22, 2023
Via
Chartmill
Looking Into Bristol-Myers Squibb's Recent Short Interest
November 21, 2023
Via
Benzinga
Why Bristol Myers Squibb Stock Is Fading Today
November 20, 2023
Via
The Motley Fool
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
November 17, 2023
Via
Benzinga
Soothing Stocks: 7 Reliable Picks to Ease Your Market Jitters
November 20, 2023
Via
InvestorPlace
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
November 20, 2023
Via
Benzinga
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
November 20, 2023
Via
Benzinga
Dutch Bros (BROS) Stock Gains on JPMorgan Upgrade
November 20, 2023
Via
InvestorPlace
Uber Stock Falls After Announcement of $1.2 Billion Convertible Notes Offering
November 20, 2023
Via
InvestorPlace
The Latest Analyst Ratings for Bristol-Myers Squibb
November 15, 2023
Via
Benzinga
Why Is Bristol-Myers Squibb (BMY) Stock Down Today?
November 20, 2023
Via
InvestorPlace
Why Is Pharma Giant Bristol-Myers Squibb Stock Trading Lower Today?
November 20, 2023
Via
Benzinga
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
November 20, 2023
From
Bristol Myers Squibb
Via
Business Wire
2 overlooked stocks that crushed earnings but traded lower
November 20, 2023
Via
MarketBeat
Exposures
Product Safety
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
November 16, 2023
Via
Benzinga
Exposures
Product Safety
Could Bristol-Myers Squibb Stock Help You Retire A Millionaire?
November 16, 2023
Via
The Motley Fool
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
November 15, 2023
From
Bristol Myers Squibb
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
November 15, 2023
Via
Benzinga
Bristol Myers Squibb Proved in Q3 Why Its Diverse Portfolio Makes It a Solid Investment
November 14, 2023
Via
The Motley Fool
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
November 14, 2023
Via
FinancialNewsMedia
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.